PMI and BAT Announce Global Patent Settlement

Rhea-AI Summary

Philip Morris International Inc (PMI) has reached a global settlement with British American Tobacco p.l.c. (BAT) that resolves ongoing patent infringement litigation related to heated tobacco and vapor products. The settlement includes non-monetary provisions, prevents future claims, and allows both parties to innovate. PMI emphasizes its commitment to continued innovation in reduced-risk products to advance Tobacco Harm Reduction and end the sale of cigarettes.

Insights

Legal Expert

The settlement between Philip Morris International Inc and British American Tobacco is a significant development within the tobacco industry, particularly in the realm of intellectual property rights and litigation. Such agreements often have substantial implications for corporate strategy and market competition. The cessation of all ongoing global patent infringement litigation allows both companies to redirect resources previously allocated for legal battles towards innovation and product development. This strategic reallocation can enhance competitiveness and potentially lead to market share gains or losses, depending on how effectively each company leverages the opportunity to innovate.

Furthermore, the settlement's prevention of future claims against current products provides a more stable and predictable operating environment. This can be attractive to investors who typically prefer reduced legal uncertainties. The ability for each party to continue innovating without the overhang of potential litigation may lead to an increase in the pace of development of reduced-risk products, which are becoming increasingly important as regulatory pressures mount against traditional smoking products. This shift has the potential to alter the landscape of the tobacco industry and impact consumer behavior, with long-term implications for public health.

Market Research Analyst

The global tobacco industry is witnessing a paradigm shift towards heated tobacco and vapor products, often marketed as reduced-risk alternatives to traditional cigarettes. The settlement between PMI and BAT could accelerate this transition by enabling both companies to focus on product innovation without the distraction of legal disputes. This is particularly relevant as both companies seek to capture a share of the growing market for smoke-free products.

From a market perspective, the resolution of patent disputes may lead to a more collaborative environment, potentially fostering cross-licensing agreements or even joint ventures in the future. This could speed up the introduction of new products and technologies, which is crucial in an industry where consumer preferences are rapidly evolving. The ability to innovate freely without the threat of litigation may also encourage other market players to invest in similar technologies, further expanding the market for reduced-risk products.

However, this settlement may also raise concerns about potential anti-competitive behavior if it leads to a concentration of market power among the largest players. Regulators and competitors will likely monitor the situation closely to ensure that the settlement does not hinder fair competition.

Financial Analyst

The announcement of a settlement between PMI and BAT is likely to be received positively by the financial markets, as it removes significant legal risk and potential financial liabilities associated with ongoing litigation. The resolution of such disputes can often result in one-time gains or losses for the companies involved, but in this case, the non-monetary nature of the settlement suggests a focus on strategic benefits over immediate financial impact.

Investors will be interested in the potential for improved profit margins due to decreased legal costs and the implications for future revenue streams from new product lines. The settlement may also have an impact on the companies' valuation, as it reflects their ability to negotiate and resolve complex legal issues, which is an important aspect of corporate governance. In the long term, the commitment to innovation in reduced-risk products could position both PMI and BAT as leaders in a growing segment of the market, which may be reflected in their stock performance.

STAMFORD, CT--(BUSINESS WIRE)-- Philip Morris International Inc (PMI) (NYSE: PM) is pleased to announce that it has reached a global settlement with British American Tobacco p.l.c. (BAT) that resolves all ongoing patent infringement litigation between the parties related to our heated tobacco and vapor products.

Patent protection is a critical component of the innovation driving PMI’s strategies and the company welcomes this settlement as the best path forward for its business plans.

The settlement includes non-monetary provisions between PMI and BAT that resolve all ongoing global patent infringement litigation, encompassing all related injunctions and exclusion orders, and prevents future claims against current heated tobacco and vapor products. The settlement also allows each party to innovate and introduce product iterations. PMI is committed to continued innovation in reduced-risk products to further advance Tobacco Harm Reduction.

"We are pleased that this matter has been resolved to the mutual satisfaction of both parties,” said Jacek Olczak, Chief Executive Officer. “There is a clear and growing global desire from adults who smoke to choose from a range of smoke-free products, and we believe continued reduced-risk category innovation can accelerate declines in the harms associated with smoking to the benefit of consumers and public health at large - as we continue PMI’s journey to end the sale of cigarettes."

EDITOR’S NOTE

A summary of the settlement between the parties will be available on the website of the Securities and Exchange Commission (SEC) in our Form 8-K filing to be filed today. Our SEC filings are available here.

Forward-Looking & Cautionary Statements

This press release contains projections of future results and goals and other forward-looking statements, including statements regarding expected financial or operational performance; investment strategies; regulatory outcomes; market expectations; and business plans and strategies. Achievement of future results is subject to risks, uncertainties and inaccurate assumptions. In the event that risks or uncertainties materialize, or underlying assumptions prove inaccurate, actual results could vary materially from those contained in such forward-looking statements. Pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, PMI is identifying important factors that, individually or in the aggregate, could cause actual results and outcomes to differ materially from those contained in any forward-looking statements made by PMI.

PMI's business risks include: excise tax increases and discriminatory tax structures; increasing marketing and regulatory restrictions that could reduce our competitiveness, eliminate our ability to communicate with adult consumers, or ban certain of our products in certain markets or countries; health concerns relating to the use of tobacco and other nicotine-containing products and exposure to environmental tobacco smoke; litigation related to tobacco use and intellectual property; intense competition; the effects of global and individual country economic, regulatory and political developments, natural disasters and conflicts; the impact and consequences of Russia's invasion of Ukraine; changes in adult smoker behavior; the impact of COVID-19 on PMI's business; lost revenues as a result of counterfeiting, contraband and cross-border purchases; governmental investigations; unfavorable currency exchange rates and currency devaluations, and limitations on the ability to repatriate funds; adverse changes in applicable corporate tax laws; adverse changes in the cost, availability, and quality of tobacco and other agricultural products and raw materials, as well as components and materials for our electronic devices; and the integrity of its information systems and effectiveness of its data privacy policies. PMI's future profitability may also be adversely affected should it be unsuccessful in its attempts to produce and commercialize reduced-risk products or if regulation or taxation do not differentiate between such products and cigarettes; if it is unable to successfully introduce new products, promote brand equity, enter new markets or improve its margins through increased prices and productivity gains; if it is unable to expand its brand portfolio internally or through acquisitions and the development of strategic business relationships; if it is unable to attract and retain the best global talent, including women or diverse candidates; or if it is unable to successfully integrate and realize the expected benefits from recent transactions and acquisitions. Future results are also subject to the lower predictability of our reduced-risk product category's performance.

PMI is further subject to other risks detailed from time to time in its publicly filed documents, including PMI's Annual Report on Form 10-K for the year ended December 31, 2022, and the Form 10-Q for the third quarter ended September 30, 2023. PMI cautions that the foregoing list of important factors is not a complete discussion of all potential risks and uncertainties. PMI does not undertake to update any forward-looking statement that it may make from time to time, except in the normal course of its public disclosure obligations.

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products. Since 2008, PMI has invested more than USD 10.5 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. In November 2022, PMI acquired Swedish Match - a leader in oral nicotine delivery - creating a global smoke-free champion led by the companies’ IQOS and ZYN brands. The U.S. Food and Drug Administration has authorized versions of PMI’s IQOS Platform 1 devices and consumables and Swedish Match’s General snus as Modified Risk Tobacco Products. As of September 30, 2023, PMI's smoke-free products were available for sale in 82 markets, and PMI estimates that approximately 19.7 million adults around the world had already switched to IQOS and stopped smoking. Smoke-free products accounted for approximately 36.2% of PMI’s total third-quarter 2023 net revenues. With a strong foundation and significant expertise in life sciences, PMI announced in February 2021 its ambition to expand into wellness and healthcare areas and, through its Vectura Fertin Pharma business, aims to enhance life through the delivery of seamless health experiences. For more information, please visit www.pmi.com and www.pmiscience.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240202036913/en/

Philip Morris International

Investor Relations:

Stamford, CT: +1 (203) 904 2410

Lausanne: +41 (0)58 242 4666

Email: InvestorRelations@pmi.com

Media: David Fraser

Lausanne: +41 (0)58 242 4500

Email: David.Fraser@pmi.com

Source: Philip Morris International

FAQ

What is the ticker symbol for Philip Morris International Inc?

The ticker symbol for Philip Morris International Inc is PM.

What is the global settlement between PMI and BAT about?

The global settlement resolves ongoing patent infringement litigation related to heated tobacco and vapor products.

What does the settlement include?

The settlement includes non-monetary provisions, prevents future claims, and allows both parties to innovate.

Where can I find a summary of the settlement between PMI and BAT?

A summary will be available on the website of the Securities and Exchange Commission (SEC) in PMI's Form 8-K filing.

What does PMI emphasize in the press release?

PMI emphasizes its commitment to continued innovation in reduced-risk products to advance Tobacco Harm Reduction and end the sale of cigarettes.